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Summary of Project Activities, 2010 
 
This narrative addresses the three broad categories of project objectives for 2010:  
(1) The development of an Unintentional Prescription Drug Poisoning Coalition to 
address the problem by reviewing relevant data and making recommendations to 
Public Health Dayton-Montgomery County and the Ohio Department of Health.  
(2) The development of a Poison Death Review process. 
(3) The facilitation and conduct of targeted Information, Training, and Educational 
Opportunities to help address and prevent the problem. 
Drug Poisoning Coalition: Community stakeholders identified in the RFP were invited to join the 
coalition. In addition, other community members who could provide specific expertise were 
recruited. The coalition consists of representatives from public health, drug treatment, 
hospitals, pharmacies, law enforcement, fire department emergency services, a medical school, 
coroner’s office, a pain clinic, the community-at-large, the alcohol, drug and mental health 
board, and Family and Children First Council (see attached Membership List). There were four 
meetings of the Drug Poisoning Coalition. Notes from these meetings are available on the 
project web site: http://www.med.wright.edu/citar/prescriptiondrugs.html. Coalition members 
prioritized activities, focusing on identifying the nature and extent of the unintentional drug 
poisoning problem in the county. They reviewed data on overdose deaths, prescriber and first 
responder views of the problem, and available research findings on the problem. The Coalition 
also reviewed information provided at Ohio Prescription Drug Abuse Action Group meetings, 
attended by the Injury Prevention Coordinator. In addition, the Coalition considered and 
approved recommendations, including the naloxone education and distribution program 
recommendation required by ODH.  
 
Poison Death Review: To develop the Montgomery County Poison Death Review process, the 
project examined Ohio’s Child Fatality Review process; reviewed other states’ death review 
mechanisms; evaluated the ODH pilot data entry form; and assessed local capacity for 
gathering, disseminating, and analyzing poisoning death data. The process met with the 
approval of the Unintentional Prescription Drug Poisoning Coalition. 
The process for review of drug poisoning deaths consists of: 
(1) Montgomery County Coroner’s Office identification of individuals whose death has been 
determined to be the result of an unintentional drug poisoning. 
(2) Coroner’s Office provision of the following data: 
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a. General information report, including case synopsis by coroner’s office 
investigator 
b. ODH Supplemental Medical Certification 
c. ODH Certificate of Death 
d. Report of postmortem examination 
e. Toxicology laboratory report 
f. Toxicology inventory of prescription drugs found at the scene of death. 
(3) Review of the data by the Unintentional Prescription Drug Poisoning project team 
(Principal Investigator, Co-Investigators, and Injury Prevention Coordinator). 
(4) Entry of the data into the database developed by the team’s data specialist. 
(5) Data analysis. 
(6) Review of data by members of the Coalition. 
A Narrative Summary of 2010 data and a Data Summary Report are included as items 2 and 
3 in this report. 
Information, Training, and Educational Opportunities: The Coalition’s principal activities related 
to this objective were to assess the need for training. The Coalition also attempted to gauge our 
ability to effectively conduct this assessment within the resources available. Finally, the 
Coalition publicized and made available a training opportunity for emergency department 
physicians and conducted a community-oriented, on-line symposium. 
This effort began with a survey of coalition members’ views of the unintentional 
poisoning death problem. The Coalition membership survey was followed by an on-line survey 
of prescribers who were identified through the Montgomery County Medical Society, the 
Dayton Dental Society, and area hospitals. These prescribers were notified by mail and asked to 
complete an on-line survey. Approximately 10% of the prescribers completed the survey. This 
assessment strategy was modified for a survey of first responders. The first responders were 
notified electronically through the membership list of the Greater Miami Valley Emergency 
Medical Services Council. The response rate to this survey was similar to that of the prescriber 
survey. The results of both surveys are posted on the Coalition web site under “Reports.” These 
surveys helped inform the development of a community-oriented, on-line symposium, 
conducted December 9, 2010. Publicity for the symposium was jointly carried out by the Wright 
State University School of Medicine and Public Health Dayton-Montgomery County. Coalition 
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members comprised the expert panel and moderators for the symposium. Participation was 
estimated by unique logins to the symposium web site and was approximately 150 individuals. 
 A Training Plan for 2011 will incorporate lessons learned from 2010 assessment 
activities. Projected activities for 2011 include expansion of on-line surveys to include 
pharmacists, substance abuse treatment providers, and the community-at-large. The Coalition 
also identified opportunities to provide OARRS training and further training with medical 
students, emergency department physicians, and first responders. An outline of the potential 
training activities for 2011 is included as item 5 in this report. 
 
 
Attached: Membership List 
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Narrative Summary of Poisoning Death Review Data, 2010 
The Montgomery County Poisoning Death Review process is informed by: 
(1) examination of Ohio’s Child Fatality Review process; 
(2) review of other states’ death review mechanisms; 
(3) evaluation of the ODH pilot data entry form; and 
(4) assessment of local capacity for gathering and disseminating poisoning death data. 
The process for review of drug poisoning deaths consists of: 
(4) Montgomery County Coroner’s Office identification of individuals whose death has 
been determined to be the result of an unintentional drug poisoning. 
(5) Coroner’s Office provision of the following data: 
a. General information report, including case synopsis by coroner’s office 
investigator 
b. ODH Supplemental Medical Certification 
c. ODH Certificate of Death 
d. Report of postmortem examination 
e. Toxicology laboratory report 
f. Toxicology inventory of prescription drugs found at the scene of death. 
(6) Review of the data by the Unintentional Prescription Drug Poisoning project team 
(Principal Investigator, Co-Investigators, and Injury Prevention Coordinator). 
(7) Entry of the data into the database developed by the team. 
(8) Review of data by members of the Coalition.  
 
Cases of Unintentional Drug Poisoning Fatalities reviewed in 2010: 81 
Date of Death for Most Recent Case Reviewed: September 12, 2010 
Estimated Completion Date for all 2010 Cases: March 15, 2010 
Unintentional Drug Poisoning Fatalities, 2008: 132 
Unintentional Drug Poisoning Fatalities, 2009: 126 
Projected Unintentional Drug Poisoning Fatalities, 2010: 130 
 
 7 
Demographic Characteristics of Population: 
 Male: 53% 
 White: 89% 
 Average Age: 40 
High School Graduate: 73% 
Single: 42% Married: 30% Divorced: 23% 
 
66% of the deaths occurred in the decedent’s home; 15% in the home of a friend; and 9% in a 
medical facility.  
Most overdose deaths (81%) occurred among individuals with a mental or physical disability. 
67% of the decedents suffered from heart disease of varying severity. 
The population consisted primarily of poly-drug users, with high rates of prescription opioid use 
(81%) and frequent exposure to sedatives, including benzodiazepines (73%). 
Coroner’s Office toxicology report data show that prescription opioids consisted primarily of 
methadone (36%), hydrocodone (30%), and oxycodone (23%). 
Alprazolam was the most prevalent benzodiazepine (56%), followed by clonazepam (25%) and 
diazepam (14%). 
There was only one death in which heroin was the only drug noted in the coroner’s toxicology 
report. There were three additional cases in which heroin was listed as the sole cause of death, 
even though other drugs were in the decedent’s system at the time of death. 
In only 36% of the cases was there a verifiable valid prescription for controlled drugs listed on 
the toxicology report. However, since no Ohio Automated Prescription Drug Reporting System 
(OARRS) data was available that could be matched to individual cases, these data reflect only 
prescription drugs found in their containers at the scene of death or in the home of the 
decedent. 
The demographic characteristics of the group of 66 opioid users were nearly identical to those 
of the other 15 individuals in the population. 
There was a relatively low incidence of overdoses (15%) that might have been prevented by the 
use of opioid antagonists by family members or fellow users. 
  
 8 
POISONING DEATH REVIEW SUMMARY REPORT, 2010 
          
Total Cases       81 
          
DEMOGRAPHICS 
Characteristic Data Source       
     Category Percent Frequency 
Age Death Certificate <15 years 0% 0 
    15-24 years 15% 12 
    25-34 years 20% 16 
    35-44 years 28% 23 
    45-54 years 19% 15 
    55-64 years 15% 12 
    65-74 years 4% 3 
    75+ years 0% 0 
Gender Death Certificate Male 53% 43 
    Female 47% 38 
Race Death Certificate White 89% 72 
    Black 11% 9 
    Other 0% 0 
Hispanic Death Certificate Hispanic/Latino 0% 0 
Education Death Certificate <High School 23% 19 
    HS graduate 73% 59 
    College graduate 1% 1 
    Post-graduate 1% 1 
Marital Status Death Certificate Single 42% 34 
    Married 30% 24 
    Divorced 23% 19 
    Separated 2% 2 
    Widowed 2% 2 
Military Death Certificate 
Ever in US Armed 










  Percent Frequency 
Physical 
Disability/Illness   81% 66 
Heart Disease   67% 54 
Mental 
Disability/Illness   33% 27 
HISTORY OF SUBSTANCE ABUSE 
    2010 
Total 
Cases 81 
Substance Abuse Data Source   Percent Frequency 
Any history 
  
  67% 54 
Alcohol   11% 9 
Cocaine   16% 13 
Marijuana   6% 5 
Methamphetamine   0% 0 
Heroin   21% 17 
Prescription opioids   26% 21 
Benzodiazepines   17% 14 
Other Prescription 
Medications   1% 1 
Over-the-Counter 
Medications   0% 0 





Characteristic Data Source Category Percent Frequency 
Location of death Case Synopsis Decedent's home 66% 53 
    Relative's home 1% 1 
    Friend's home 15% 12 
    Place of work 0% 0 
    School 0% 0 
    Hospital 9% 7 
    Drug tx facility 0% 0 
    
Jail/detention 
area 0% 0 
    Public area 3% 2 
    Other 6% 5 
911 called Case Synopsis Yes 94% 75 
Person reporting 
death Case Synopsis Coroner 1% 1 
    Hospital physician 19% 15 
    Other physician 0% 0 
    Mortician 0% 0 
    EMS/Police 80% 64 
Possible prevention 











TOXICOLOGY REPORT         
    2010 
Total 
Cases 81 




Alcohol 23% 19 
Illicit Drugs Marijuana 31% 25 
  Cocaine 31% 25 
  Methamphetamine 1% 1 
  Hallucinogen 0% 0 
  Heroin 28% 23 
Prescription Opioids Any 81% 66 
  Oxycodone 23% 19 
  Hydrocodone 30% 24 
  Methadone 36% 29 
  Fentanyl 6% 5 
  Tramadol 7% 6 
  Hydromorphone 1% 1 
  Morphine 7% 6 
  Propoxyphene 2% 2 
  Meperidine 0% 0 
  Buprenorphine 0% 0 
  Other 2% 2 
Anti-Depressants Any 44% 36 
Sedatives (Including 
Benzodiazepines) Any 77% 62 
Benzodiazepine Any 73% 59 
Any Prescription 
Opioid + Any Anti-
Depressant   37% 30 
Any Prescription 
Opioid + Any 
Benzodiazepine   64% 52 
Any Prescription 
Opioid + Any 
Benzodiazepine, BUT 
WITHOUT Heroin or Anti-
Depressants   27% 22 
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Any Prescription 
Opioid, Without Heroin or 
any Sedative--disregarding 




  11% 9 
Heroin+ Any 
Prescription Opioid 
AND/OR Any Sedative   21% 17 
Heroin WITHOUT 
Alcohol, Prescription 
Opioids, Sedatives or Anti-
Depressants   1% 1 
Other Prescription Any 49% 40 
Over-the-counter Any 20% 16 
Verifiable Valid 
Prescription for Controlled 
Drugs in Tox Report 
Case Synopsis 
and Postmortem 
Report   36%   
 
 
PRESCRIPTION OPIOIDS     







Opioids:     66 81% 81 
Age 
Death 
Certificate <15 years 0 0% 0% 
    15-24 years 9 14% 11% 
    25-34 years 13 20% 19% 
    35-44 years 17 26% 32% 
    45-54 years 15 23% 19% 
    55-64 years 11 17% 15% 
    65-74 years 1 2% 4% 
    75+ years 0 0% 0% 
Gender Death Certificate Male 33 50% 55% 
    Female 33 50% 45% 
Race Death Certificate White 60 91% 89% 
    Black 6 9% 11% 
Hispanic Death Certificate Hispanic/Latino 0   0% 
 13 
Education Death Certificate <High School 16 24% 26% 
    HS graduate 49 73% 66% 
    College graduate 1 1% 0% 
    Post-graduate 1 1% 0% 
Marital Status Death Certificate Single 27 41% 38% 
    Married 23 35% 28% 
    Divorced 13 20% 26% 
    Separated 1 2% 0% 
    Widowed 2 3% 2% 
Military Death Certificate 
Ever in US Armed 




and Report Any 56 85% 85% 
Heart Disease 
Case Synopsis 
and Report   44 67% 73% 
Verifiable Valid 




Summary of Unintentional Prescription Drug Poisoning Literature from Peer Reviewed, 
Public, and Media Sources 
 
12 Recent Articles on Unintentional Prescription Drug Poisoning, from Peer Reviewed and 
Government Sources: 
 
Beletsky L, Burris S, and Kral A. Closing death’s door: action steps to facilitate emergency 
opioid drug overdose reversal in the United States: A Conference Report from The Center 
for Health Law, Politics and Policy Temple University Beasley School of Law. Electronic copy 
available at: http://ssrn.com/abstract=1437163 
A comprehensive conference report with recommendations 
CDC. CDC's issue brief: unintentional drug poisoning in the United States. March 19, 
2010/59(10);300. Available at: 
http://www.cdc.gov/homeandrecreationalsafety/poisoning/brief.htm 
What the CDC is doing, and links to some State responses to the epidemic 
Cicero, Theodore J.; Lynskey, Michael; Todorov, Alexandre; Inciardi, James A.; Surratt, Hilary 
L. Co-morbid pain and psychopathology in males and females admitted to treatment for 
opioid analgesic abuse. Pain Vol 139(1)2008 p.127-135 Elsevier Science, Netherlands 
A description of a population of 1408 individuals admitted for opioid abuse treatment in 
the US 
Dormitzer C. Summary of drug abuse "rates" in the United States. Available at: 
http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4356s1-04-fda-
corepresentations.ppt   (Starts on slide 13 of link provided) 
 
Gaston RL, Best D, Manning V, Day1 E. Can we prevent drug related deaths by training 
opioid users to recognise and manage overdoses? Harm Reduct J. 2009; 6: 26. 
The need for a naloxone implementation model 
Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical 
overdose fatalities. JAMA 2008;300:2613-20. 
An examination of all West Virginia pharmaceutical overdose deaths in 2006 
Kim D, Irwin K, and Khoshnood K. Expanded Access to Naloxone: Options for Critical 
Response to the Epidemic of Opioid Overdose Mortality. American Journal of Public Health 
March 2009, Vol 99, No. 3. Electronic copy available at: 
http://www.ajph.org/cgi/doi/10.2105/AJPH.2008.136937 
Paulozzi, Leonard J.; Annest, Joseph L. US data show sharply rising drug-induced death 
rates. Injury Prevention. Vol 13(2), Apr 2007, 130-132. 
Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 
2007: area profiles of drug-related mortality. Rockville, MD: Substance Abuse and Mental 
Health Services Administration; 2009. HHS publication no. SMA 09-4407. Available at: 
http://dawninfo.samhsa.gov/pubs/mepubs 
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Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 
2007: national estimates of drug-related emergency department visits. Available at: 
http://dawninfo.samhsa.gov/files/ed2007/dawn2k7ed.pdf 
Substance Abuse and Mental Health Services Administration. Results from the 2008 
National Survey on Drug Use and Health: national findings. Rockville, MD: Substance Abuse 
and Mental Health Services Administration; 2009. HHS publication no. SMA 09-4434. 
Available at: http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8results.cfm 
Warner M, Chen LJ, Makuc DM. Increase in fatal poisonings involving opioid analgesics in 
the United States, 1999--2006. NCHS data brief, no 22. Hyattsville, MD: National Center for 
Health Statistics; 2009. 
 
UNINTENTIONAL PRESCRIPTION DRUG POISONING LITERATURE 
Description of Problem and Population 
Adams, Edgar H.; Breiner, Scott; Cicero, Theodore J.; Geller, Anne; Inciardi, James A.; 
Schnoll, Sidney H.; Senay, Edward C.; Woody, George E. A Comparison of the Abuse Liability 
of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic Pain. Journal of Pain and 
Symptom Management Vol 31(5)2006 p.465-476 Elsevier Science, Netherlands. 
http://www.ncbi.nlm.nih.gov/pubmed?term=16716877 
Arkes, J. and Iguchi, M.Y., (Fall 2008) How Predictors of Prescription Drug Abuse Vary by 
Age. Journal of Drug Issues, 0022-0426/08/04 Vol. 38 (4) p. 1027-1044. 
http://www.ncjrs.gov/App/Publications/abstract.aspx?ID=248641  
Birnbaum HG, White AG, Reynolds JL, Greenburg PE, Zhang M, Vallow S, et al. Estimated 
costs of prescription opioid analgesic abuse in the U.S. in 2001;Clin J Pain 2006;22:667–76. 
http://www.ncbi.nlm.nih.gov/pubmed?term=16988561 
Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin 
Abuse Among Patients Entering Addiction Treatment. Am J Psychiatry. 2007 November; 
164(11): 1750–1756.  
http://www.ncbi.nlm.nih.gov/pubmed?term=17974941 
Cicero, Theodore J.; Inciardi, James A. Diversion and Abuse of Methadone Prescribed for 
Pain Management. JAMA: Journal of the American Medical Association Vol 293(3)2005 
p.297-298 American Medical Assn, US. 
http://www.ncbi.nlm.nih.gov/pubmed?term=15657321 
Cicero, Theodore J.; Lynskey, Michael; Todorov, Alexandre; Inciardi, James A.; Surratt, Hilary 
L. Co-morbid pain and psychopathology in males and females admitted to treatment for 
opioid analgesic abuse. Pain Vol 139(1)2008 p.127-135 Elsevier Science, Netherlands  
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Dasgupta N, Mandl ND, Brownstein JS. Breaking the News or Fueling the Epidemic? 
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Narrative Summary Naloxone Literature Reviews 
Background: 
Drug overdoses have overtaken such high-profile causes of death as AIDS and homicide as a 
leading cause of accidental injury death in the U.S. (Sporer et al., 2007).  In Ohio, unintentional 
poisoning has already surpassed motor vehicle accidents as the leading cause of accidental 
death (Ohio Department of Health, 2009). Opioid drugs are driving this surge, contributing to 
the deaths of over 16,000 Americans each year. “With better availability of opioid 
pharmaceuticals to treat serious pain, prescription drugs have become a substantially bigger 
source of overdose risk, though research on the key risk factors for pharmaceutical opioid 
overdose, its circumstances, and successful intervention strategies remains too sparse. 
Although more research is needed, it is abundantly clear that timely, coordinated, and well-
balanced action is necessary to assure that society can get the benefits of adequate pain care 
while minimizing overdose risk” (Beletsky, 2008). 
 
Naloxone’s potential for preventing opioid overdose deaths: 
Naloxone is an effective opioid antagonist. If it is injected soon after an opioid overdose, 
naloxone prevents and reverses the effects of opioids on the brain and restores respiration. 
When given intramuscularly, the onset of action is about two minutes. One benefit of naloxone 
in preventing overdoses, is that it exhibits essentially no pharmacological activity in the absence 
of the agonist effects of opioids. It is an inexpensive, non-scheduled drug available by 
prescription only through medical professionals (Green et al., 2008; Tobin et al., 2005). 
 
Description of efforts to employ naloxone in opioid overdose prevention: 
The Food and Drug Administration approved naloxone in 1971 for complete or partial reversal 
of narcotic depression. Naloxone has been used by emergency medical personnel for more than 
three decades. However, peers or family members are often in the best position to respond to 
overdose symptoms. Data from pilot programs suggest that lay persons can be consistently 
successful in administering naloxone to reverse opioid overdose (Kim, 2009).  
 
Many states and localities are attempting to expand access to naloxone to intravenous drug 
users and their peers as a public health intervention for reducing overdose deaths. To do so, 
several states (California, Connecticut, Illinois, Maryland, Massachusetts, Oregon, Pennsylvania, 
New Mexico, New York, North Carolina, and others) have pilot programs or established 
programs for naloxone distribution among drug users. Many of these programs claim 
impressive declines in their overdose mortality numbers, 17–20% in some cases (Green et al., 
2008). 
 
Results from programs that employ naloxone in opioid overdose prevention: 
Although naloxone distribution to drug users has been ongoing in several U.S. jurisdictions, few 
formal, empiric evaluations have been conducted and published in the peer-reviewed literature 
(Baca and Grant, 2005). Syringe exchange and methadone maintenance programs in San 
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Francisco, Baltimore, and New Mexico have distributed naloxone to injection drug users (IDUs) 
and their peers (Seal et al., 2005), but these programs have not been rigorously evaluated. 
Evidence from a program in Chicago suggests that there was a 30% decrease in overdose 
deaths concurrent with the implementation of a citywide naloxone distribution program 
(Maxwell et al., 2006). Two U.S.-based formal evaluations of naloxone distribution programs, 
involving small numbers of individuals (24 IDUs in San Francisco (Seal et al., 2005) and 25 IDUs 
in NYC (Galea et al., 2006)) were conducted in the last 10 years. The pilot project evaluations 
suggested that distribution of naloxone to drug users was feasible and that it might be 
associated with reduction in overdose mortality (Piper et al., 2008).  
 
Descriptions of Some Current Naloxone Distribution Programs:  
Project Lazarus, Wilkes County, NC 
Goals for participants: 
• Recognize the signs of overdose 
• Understand the importance of calling 911 
• Perform rescue breathing 
• Administer intranasal naloxone 
• Obtain treatment for substance abuse and misuse 
Participants: Injection drug users and others at risk of opioid overdose, receiving 
prescribed naloxone 
Research Results: None available. 
Overdose Prevention Project, Prevention Point Pittsburgh 
Goals: 
• Teach people who use drugs how to prevent and respond to overdose 
• Reduce obstacles to calling 911 
• Make naloxone directly accessible to individuals who use drugs and are 
most often present when overdoses occur 
Participants: 336 individuals likely to be at risk of opioid overdose or likely to be 
present, receiving prescribed naloxone 
Research Results: Survey of 173 program participants who used naloxone:  
• 172 reported successful use of naloxone 
• One death reported – suspected suicide 
• 90 reported performing rescue breathing in addition to naloxone 
administration (61%). 
• Evaluation of program found no increase in drug use among program 
participants as a result of having naloxone 
• Out of 153 cases where 911 was not called, 95 (72%) gave the reason for 
not calling 911 as “fear of police involvement” (Prevention Point 
Pittsburgh, 2007). 
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Staying Alive, Baltimore, MD 
Goals: Teach participants how to: 
• Prevent overdose 
• Recognize overdose symptoms 
• Perform rescue breathing 
• Call 911 
• Administer naloxone 
Participants: 85 injection drug users receiving Staying Alive training 
Research Results: 
• 43 participants reported having witnessed an overdose 
• Post-training, naloxone was administered by 19 with no reported adverse 
effects 
• Post-training, a greater proportion of participants reported using 
resuscitation skills taught in the SA program along with increased 
knowledge specifically about naloxone 
• “Results from this study provide additional evidence to support the 
effectiveness of overdose prevention training programs that include skills 
building for drug users to administer naloxone” (Tobin et al., 2009)  
Skills and Knowledge on Overdose Prevention (SKOOP), New York, NY 
Goals: 
• Reduce overdose-related deaths through the distribution of naloxone 
hydrochloride to injection drug users in NYC 
• Build evidence for the effectiveness of take-home naloxone in harm 
reduction settings 
• Create wider support for the inclusion of naloxone in harm reduction, 
methadone, and other public health programs 
 
Participants: 1004 injection drug users, 122 participating in the research arm of the 
program. All were given a prescription for naloxone by a physician. Participants in 
SKOOP were over the age of 18 and current or former drug users. 
Research Results:  
• Naloxone was administered 82 times 
• 68 (83.0%) persons who had naloxone administered to them lived, and 
the outcome of 14 (17.1%) overdoses was unknown 
• Ninety-seven of 118 participants (82.2%) said they felt comfortable to 
very comfortable using naloxone if indicated 
• 94 of 109 (86.2%) said they would want naloxone administered if 
overdosing 
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• Naloxone administration by IDUs is feasible as part of a comprehensive 
overdose prevention strategy and may be a practicable way to reduce 
overdose deaths on a larger scale (Piper et al., 2008) 
England, United Kingdom 
Goal: Train participants in overdose management and naloxone administration 
 
Participants: 239 opiate users, recruited from across 20 drug services in England. 
Eighty (34%) were attending in-patient services, 149 (62%) attending out-patient 
services and 10 (4%) attending criminal justice intervention programs in the South 
East, South West, Midlands and North of England. 
 
Research Results:  
• Training in management of overdose can be given successfully to drug 
users in treatment, resulting in substantially improved knowledge and 
competence 
• The training is followed by implementation in subsequent overdose 
situations, detectable even within a 3-month follow-up period 
• No unexpected adverse reactions were identified 
• Beyond the high numbers of drug users trained within the clinical 
services, this knowledge was spread further to family and peers 
• There is considerable evidence of benefit to others—drug-users other 
than the patient to whom the naloxone was given (Strang et al., 2008) 
 
 
Factors influencing implementation of naloxone distribution programs: 
Training: 
 “Receipt of training and higher perceived competency in recognizing signs of an opioid 
overdose were associated independently with higher overdose recognition scores. 
Trained respondents were as skilled as medical experts in recognizing opioid overdose 
situations (weighted kappa = 0.85) and when naloxone was indicated (kappa = 1.0). 
Results suggest that naloxone training programs in the United States improve 
participants’ ability to recognize and respond to opioid overdoses in the community. 
Drug users with overdose training and confidence in their abilities to respond may 
effectively prevent overdose mortality”. (Green et al., 2008). 
 
 
Attitudes of Providers and First Responders 
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 “Overall attitudes [of first responders] toward training drug users to administer 
naloxone were negative with 56% responding that this training would not be effective in 
reducing overdose deaths” (Beletsky, 2008). 
Provider concerns included drug users’ inability to properly administer the drug, 
program condoning and promoting drug use, and unsafe disposal of used needles. 
Incorporating information about substance abuse and harm reduction approaches in 
continuing education classes may improve the attitudes of provider toward naloxone 
training programs (Tobin et al., 2009). 
“Less than one in four of the respondents in our sample [physicians] reported having 
heard of naloxone prescription as an intervention to prevent opiate overdose, and the 
majority reported that they would never consider prescribing the agent and explaining 
its application to a patient. Factors predicting a favorable attitude towards prescribing 
naloxone included fewer negative perceptions of IDUs, assigning less importance to 
peer and community pressure not to treat IDUs, and increased confidence in ability to 
provide meaningful treatment to IDUs. Our data suggest that steps to promote naloxone 
distribution programs should include physician education about evidence-based harm 
minimization schemes, broader support for such initiatives by professional 
organizations, and policy reform to alleviate medico-legal concerns associated with 
naloxone prescription. FDA re-classification of naloxone for over-the-counter sales and 
promotion of nasal-delivery mechanism for this agent should be explored” (Ruthhauser 
et al., 2007). 
Privacy and Legal Liability Concerns:  
“Research in the domain of heroin use suggests that witnesses to overdose involving 
illegal drugs are reluctant to call 911 out of fear of police involvement and mistrust of 
health care providers” (Beletsky, 2008). 
“A number of states have initiated ‘good Samaritan’ laws to protect from legal recourse 
citizens who carry and administer naloxone and medical professionals who prescribe it 
(e.g. Connecticut, Illinois, New York)” (Green et al., 2008). 
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Summary of Discussions with Naloxone Distribution Program 
Representatives 
 
Maya Doe-Simkins, MPH; Boston Medical Center 
Program operated by Boston Public Health Commission 
• Authorized in 2006, by Boston Public Health Commission (BPHC) regulation 
• Intranasal naloxone education and distribution of the spray to potential 
bystanders 
• Participants taught by trained nonmedical needle exchange staff 
• After 15 months, the program provided training and intranasal naloxone to 385 
participants who reported 74 successful overdose reversals 
• Results published in Am J Public Health. 2009;99:788-791. 
doi:10.2105/AJPH.2008.146647. 
Key Findings: 
Needle-exchange participants experienced and witnessed high rates of overdoses. 
Needle-exchange participants successfully recognized overdose and used intranasal 
naloxone to reverse potentially fatal opioid overdoses. 
Overdose prevention programs can provide training and distribute intranasal naloxone 
without a direct clinical health care provider-patient encounter. 
Overdose prevention programs that include the distribution of intranasal naloxone by 
nonmedical personnel are feasible for city public health departments. 
 
Issues to Consider Relative to Montgomery County:  
• BPHC distribution program population is more African-American, male, heroin 
injecting 
• IN is standard 
• Program going state wide  
Nabarun Dasgupta, Department of Epidemiology, University of North Carolina 
Program:  Project Lazarus Wilkes County, North Wilkesboro, North Carolina 
http://www.harmreduction.org/downloads/North%20Carolina%20Naloxone%2007.pdf 
• Funded by the Northwest Community Care Network (NCCN, the regional 
Medicaid authority),  Drug Policy Alliance,  Wilkes County Health Department, 
doctor's offices and the pharmaceutical industry 
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• Started in 2008 
• No published peer reviewed evaluation 
Key Initial Finding: 
Project Lazarus estimates that if a single hospital encounter were prevented, a savings 
of $20,468 to $31,083 would be realized, including prevention of productivity loss. 
 
Issues to Consider Relative to Montgomery County:  
• Similar population demographics and drug use patterns 
• Much more rural 
• Program engages doctors and other prescribers 
• Requires watching 20 minute video prior to receiving naloxone 
• Requires designating family member or other to receive education 
• Education conducted at physician’s office or point of sale (retail pharmacy) 
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Naloxone Fact Sheet 
 
Published by: Harm Reduction Coalition 
Available at: http://www.harmreduction.org/article.php?id=529 
 
Naloxone (also known as Narcan®) is a medication used to counter the effects of opioid 
overdose, for example morphine and heroin overdose.  Specifically, naloxone is used in opioid 
overdoses to counteract life-threatening depression of the central nervous system and 
respiratory system, allowing an overdosing victim to breathe normally.  Naloxone is a 
nonscheduled (i.e., non-addictive), inexpensive (less than $2 per dose) prescription medication 
with the same level of regulation as prescription ibuprofen.  Naloxone only works if a person 
has opioids in their system; the medication has no effect if opioids are absent. 
 
Although traditionally administered by emergency response personnel, naloxone can be 
administered by minimally trained laypeople, which makes it ideal for treating overdose in 
people who have been prescribed opioid pain medication and in people who use heroin and 
other illicit opioids. 
 
The federal Centers for Disease Control and Prevention reports that drug overdose is a growing 
problem and that the rate of deadly drug overdoses has increased nearly 70% since 1999.  
Overdose is second only to motor vehicle crashes as the leading cause of unintentional injury 
death in the United States.  It is the leading cause of death among people who inject drugs, and 
increasingly common among individuals taking prescription narcotics.     
 
Naloxone Distribution Programs 
 
In most jurisdictions naloxone is only available to people experiencing overdose when 
emergency medical services are summoned.  However, recognizing that many fatal opioid 
overdoses are preventable, a number of jurisdictions in California and throughout the United 
States are providing overdose prevention, recognition, and response training.  These include 
training in calling 911, performing rescue breathing, and take-home prescriptions of naloxone 
to drug users and their community.   
 
Studies indicate that many victims of opioid overdoses never receive proper medical attention 
because their peers and other witnesses (who are often drug users themselves) do not call 911, 
for fear of police involvement.  While not all opioid overdoses are fatal, the provision of 
naloxone to those who would otherwise not receive it could save hundreds of lives each year.  
Additionally, timely provision of naloxone may help reduce some of the morbidities associated 
with non-fatal overdose.  Witnesses who are able to provide rescue breathing and naloxone to 
an overdose victim experiencing respiratory depression will likely prevent brain damage in the 
victim (brain damage begins within 3-5 minutes after someone stops breathing). 
 
In Cook County Illinois, the first naloxone distribution program in the United States, operated 
by the Chicago Recovery Alliance, helped to bring down the number of overdose deaths from 
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466 in 2000 to 324 in 2003.  Dan Bigg, director of the program, said that since 1997 they have 
reported at least 745 episodes of reversed opiate overdoses—most or all of which would have 
been fatal. 
 
Since November 2003 the Harm Reduction Coalition’s Drug Overdose Prevention & Education 
Project has collaborated with the San Francisco Department of Public Health to provide 
overdose prevention, recognition, and response training as well as naloxone prescriptions to 
over 1,100 drug users and has heard back from over 270 of them that they have used naloxone 
to reverse an overdose.   
 
Policy Reform to Support Effective Opioid Overdose Response 
 
Although naloxone has no effect on someone not on opioids and has almost no side effects 
when administered to someone on opioids, other than the effects of withdrawal in opioid-
dependent individuals, some clinicians are concerned about providing take-home naloxone for 
use by lay people.  Clinicians voice concerns that patients may use naloxone on a third party 
experiencing and overdose and, in the event of an adverse reaction, the clinician could be held 
liable. 
 
In New York, New Mexico, and Connecticut legislation was enacted to address the issue of 
health care provider and third party liability.  This legislation provides specific immunities to 
health care providers and third persons who are involved in the distribution and/or 
administration of naloxone.  For example, it is well documented that many drug users fear 
calling 911 to summon emergency medical response for fear of police involvement.  New 
Mexico’s Good Samaritan legislation provides limited immunity from prosecution for a person 
who seeks or obtains medical assistance for a drug-related overdose.  In New York State, the 
naloxone liability legislation passed unanimously and the Governor signed the bill into law 
without opposition from constituent groups.   
 
California Senate Bill (SB) 767, the Overdose Treatment Liability Act, was signed by Governor 
Schwarzenegger and went into effect on January 1, 2008.  Senator Ridley Thomas’ bill, 
cosponsored by the Harm Reduction Coalition (HRC), the County of Los Angeles, and the Los 
Angeles Overdose Taskforce creates a 3 year pilot project in seven counties: Alameda, Fresno, 
Humboldt, Los Angeles, Mendocino, San Francisco, and Santa Cruz, to authorize overdose 
prevention programs and protect providers who prescribe take-home naloxone to people who 
use opiates and may be at risk of an overdose.  While the legislation does not protect a third 
party who administers naloxone in an overdose event, the legislation will encourage more 
medical providers to prescribe and dispense this life-saving drug in California. 
 
To support effective overdose response among communities of illicit drug users, policy reforms 
are essential.  Amnesty from arrest and/or prosecution for those who witness an overdose and 
summon emergency medical services is required.  Funding is needed to sustain or expand 
current naloxone distribution programs and create new programs in areas where none exist.  
Best practices and training guidelines that encourage and support overdose prevention in a 
variety of harm reduction and primary care settings should be culled and distributed by both 
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federal and local health jurisdictions.  Finally, national, state, and local surveillance of drug-
related overdoses is necessary in providing the most immediate and effective overdose 
prevention strategies to licit and illicit opioid users.    
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Overview of Naloxone Effectiveness, Costs, and Barriers to Use 
1. Effectiveness and Cost Effectiveness of Naloxone Distribution 
Reversal Rates from Various Naloxone Distribution Programs 
New York City Department of Health and Mental Hygiene: 
3% (25 overdose reversals among 754 trainees provided with kits) during the first six 
months of program implementation 
7% (104/1,485) after 12 months. 
9% (162/1,800) after 18 months 
Drug Overdose Prevention and Education (DOPE) Project, San Francisco: 24% (170/700) 
Staying Alive, Baltimore, MD: 14% (131/951) 
Chicago Recovery Alliance: 7% (446/6,000) 
Heller, D.I. & Stancliff, S. (2007). Providing naloxone to substance users for 
secondary administration to reduce overdose mortality in New York City, Public 
Health Reports, 122 (3), 393-397. 
Cost Effectiveness, Project Lazarus, Wilkes County, North Carolina 
Mean cost of inpatient hospitalization for accidental prescription opioid poisoning in 
North Carolina: $12,379 (Agency for Healthcare Research and Quality, 2007). 
 
Loss of productivity due to poisoning in US: $18,704 (Corso, Finkelstein et al. 2006). 
 
Project Lazarus estimates that if a single hospital encounter were prevented, a savings 
of $20,468 to $31,083 would be realized, including prevention of productivity loss. 
   http://www.harmreduction.org/downloads/North%20Carolina%20Naloxone%2007.pdf 
2. Cost Estimates for Naloxone Distribution in Ohio 
a. Injectable Naloxone; $1-2 per dose (usually two doses provided) 
b. Intra-nasal Naloxone Kit: $25-30 
3. Prescription Status of Naloxone 
Beletsky, L., Burris, S., & Kral A. (2008). Closing death’s door: Action steps to facilitate 
emergency opioid drug overdose reversal in the United States. A Conference Report from 
the Center for Health Law, Politics and Policy Temple University Beasley School of Law. 
 
Although it is an opioid derivative, naloxone is not classified as a controlled substance in 
Ohio. This reduces the level of regulatory control over its possession and use, but the drug is 
still classified by the FDA as requiring a prescription. 
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The prescription requirement creates several hurdles for naloxone distribution programs. 
First, it means programs must have medical personnel authorized to issue prescriptions, 
which can raise costs and add logistical complexity. Because health professionals have to be 
involved, these programs must deal with practitioner concerns about malpractice liability.  
Second, before the drug can properly be provided to an overdose prevention program 
participant, a licensed healthcare professional authorized to issue prescriptions must 
complete an exam or another interaction with a patient (as required by state law) and give 
the patient information about the indications for the drug, its proper use, and its risks and 
benefits. While some of these functions can be delegated to allied health providers working 
under standing orders or other appropriate practice guidelines, the medical model is 
cumbersome and limits the discretion of programs to follow other procedures that may be 
appropriate and supported by evidence. In some states medical boards have agreed to an 
abbreviated medical encounter for naloxone prescribing, similar to the reduced 
requirements underlying community-based seasonal influenza vaccination. Many states 
make it a crime to possess a prescription drug without a prescription, so participants in 
naloxone distribution programs are potentially in jeopardy if they do not have, or fail to 
carry, a prescription.  
 
Finally, the prescription requirement limits who takes part in overdose prevention 
programs. In strict legal terms, a prescription is only appropriate if it is issued to a patient 
for the patient’s own medical need. A lay person who is not a drug user but is trained to 
help others at risk of overdose, strictly speaking, has no personal medical need for the drug. 
Moreover, providing naloxone under those terms would amount to deputizing the lay 
person as a medical practitioner, which contravenes the basic idea of licensure and criminal 
laws that prohibit the unlicensed practice of medicine.  
 
Though unlikely to give rise to real legal problems in fact, concerns about issues related to 
naloxone’s prescription status present obstacles for the planning and implementation of 
overdose education and prevention initiatives. The limitation on prescribing to lay persons 
has been a particular problem, holding up the start of programs for months or years in 
some places.  
 
4. Good Samaritan Laws 
http://www.ohiobar.org/Pages/LawYouCanUseDetail.aspx?itemID=477 
Ohio’s Law 
a. Q.: What is the “Good Samaritan” law? 
A.: The “Good Samaritan” law provides certain protection from lawsuits to 
people who give first aid or other emergency care or treatment to someone 
suffering an injury or sudden illness. This statute is listed in the Ohio Revised 
Code, Section 2305.23. 
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b. Q.: Under what circumstances does the Good Samaritan law apply? 
A.: The care or treatment must be given at the scene of an emergency outside of 
a hospital, doctor’s office, or other medical facility. The law protects volunteers 
who help when someone becomes ill or is injured in places such as on the street 
or highway, in parks, restaurants, businesses, even private residences. If 
someone is already at a hospital or other medical facility, the law does not apply. 
c. Q.: Are there any limits to the protection of the Good Samaritan law? 
A.: The law does not protect against lawsuits or criminal charges for “willful or 
wanton” (intentional or malicious) misconduct.  Examples of willful or wanton 
misconduct would include stealing from an accident victim or inappropriate 
sexual touching.   
 
Also, if the person providing the emergency care or treatment is paid or expects 
to get paid for giving the care or treatment, whether by the victim or someone 
on behalf of the victim (such as an insurance company), the Good Samaritan law 
does not provide protection. This is because a person who is paid generally is not 
considered a volunteer, and the Good Samaritan law is intended to protect those 
who volunteer in emergencies.  The statute provides one exception to this not-
being-paid rule:  An on-duty police officer or fire fighter who gives emergency 
care or treatment may be covered by the Good Samaritan law. The reasoning is 
that, even though the police officer or firefighter is being paid by the department 
for working a shift (or responding to a call-out in the case of volunteer 
firefighters), payment is not being provided specifically for giving care to a 
particular individual in an emergency.        
d. Q.: Does the Good Samaritan law protect doctors, nurses, and other health 
care professionals? 
A.: Yes, if the health care professional volunteers her/his services at the scene of 
an emergency that is outside a hospital, doctor’s office or other medical facility. 
However, a professional who seeks payment for this volunteer emergency care 
or treatment loses the protection under the Good Samaritan law.  
Ohio does not have a Good Samaritan Law specifically designed to protect people who 
report an overdoses. 
New Mexico was the first state with a Good Samaritan Law to protect people who 
report an overdose, passed in 2007. Washington passed such a law in 2010. According 
to the National Conference of State Legislatures, Hawaii, Massachusetts, Minnesota, 
and Rhode Island are considering similar measures. 
Under Washington’s law, if someone seeks assistance for an individual who has 
overdosed, neither party can be prosecuted for drug possession. Good Samaritans 
could, however, be charged with manufacturing or selling drugs. The bill also allows 
people to use naloxone, if it is used to help prevent an overdose. 
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5. Legal and Regulatory Barriers to Implementing an Overdose Prevention Program With 
Intranasal Naloxone Distribution by Nonmedical Personnel 
Seal,  K. H., Thawley, R., Gee, L., Bamberger, J., Kral, A. H., Ciccarone, D., Downing, M., & 
Edlin, B. R. (2005). Naloxone distribution and cardiopulmonary resuscitation training for 
injection drug users to prevent heroin overdose death: A pilot intervention study. 
Journal of Urban Health, 82 (2), 303-11. 
Barrier: 
 
Nonmedical personnel are not authorized to distribute prescription medication and are 
not authorized to administer a prescription medication to a person who has not been 




The standard of care for the use of naloxone has for decades included use by pre-
hospital personnel in nonclinical settings operating under standing orders from 
physicians who are neither on-site nor directly supervising. 
 
Other life saving prescription medications, such as epinephrine injectors for 
anaphylactic shock, and other devices, such as automated external defibrillators, are 
used by bystanders and nonmedical personnel. 
 
Other states, such as New Mexico, New York and Connecticut, have addressed this 
by passing laws that limit the liability of medical and nonmedical personnel who 
administer and distribute potentially lifesaving medication. 
 
A study of 6 programs that train bystanders to recognize and respond to opioid 
overdose by using naloxone has demonstrated that trained potential bystanders are 
similarly skilled as medical experts in recognizing opioid overdose situations and 
when naloxone is indicated. 
 
A local public health regulation was passed by BPHC, the City of Boston's board of 
health, identifying the overdose-prevention naloxone distribution program as an 
official public health program and assuming liability for the work of medical and 
non-medical personnel involved in the program. Under the medical license of the 
Medical Director of Boston Emergency Medical Services, potential bystanders 
received a standard curriculum about overdose prevention with instructions and 
demonstration of how to properly use the medication. Receipt of this curriculum 









Prescriptions drugs may be and are routinely given for any indication not explicitly 
prohibited by law. 
 
While no large scale randomized clinical trials have been conducted, intranasal 
naloxone has been evaluated in several research studies, with little evidence of 
adverse events. A small randomized trial comparing intranasal with intramuscular 
delivery of naloxone used by emergency personnel demonstrated that intranasal 
delivery had a longer time to clinical response (8 minutes vs 6 minutes), but less 
agitation or irritation (2% vs 13%). 
 
Intranasal naloxone is a first-line treatment for opioid overdose among emergency 






Potential Training Activities, 2011 
The Coalition engaged in a variety of training activities in 2010—coalition member, prescriber, 
and first responder needs assessments, small group training, and a community on-line 
symposium. Based on a review of those activities, we anticipate conducting the following 
activities in 2011:  
1. Needs Assessment: 
a. Increase understanding of local issues bearing on drug overdoses and inform 
training activities by using on-line surveys of: 
i. Pharmacists 
ii. Substance abuse treatment providers 
iii. Community-at-large 
b. Evaluate Dayton Area Drug Survey data to inform involvement of health care 
providers in curriculum development for Miami Valley area high school students. 
c. Evaluate symposium responses to determine effectiveness of the on-line symposium 
and determine next steps relative to on-line efforts. 
i. On-line training for OARRS 
ii. On-line training of medical students, emergency department personnel, first 
responders (especially concerning issues bearing on naloxone distribution), 
dentists 
iii. Consider CEUs and BRCHs for providers 
2. Using November brief OARRS training as a model, implement OARRS training: 
a. WSU medical students 
b. Emergency department physicians 
c. Grand Rounds and other venues 
3. Conduct four unintentional prescription drug overdose-related training sessions: 
a. WSU medical students 
b. Grand Rounds at area hospitals 
c. First responder training through the Emergency Medical Services Council 





The Montgomery County Unintentional Poisoning Death Coalition makes the following 
recommendations: 
1. Needs Assessment & Training 
a. Increase understanding of local issues bearing on drug overdoses by using on-line 
surveys and training modules: 
i. Physicians 
ii. Dentists 
iii. First Responders 
iv. Pharmacists 
v. Substance abuse treatment providers 
vi. Community-at-large. 
b. Using November brief OARRS training as a model, implement OARRS training with 
medical students, physicians, dentists, podiatrists. 
c. Evaluate responses to symposium to determine effectiveness of on-line symposium 
and determine next steps relative to on-line efforts. 
d. The Dayton Area Drug Survey identifies increases in use of tranquilizers and 
prescription opiates by Miami Valley area high school students. This suggests an 
opportunity for developing curricula for area schools. 
2. Poison Death Review 
e. Pursue possible electronic data transfer from Montgomery County Coroner’s Office 
to WSU. 
f. Continue currently established PDR process. 
g. Continue routine summary of data for Coalition. 
3. Other 
h. Analyze Greater Dayton Area Hospital Association data on overdoses. 
i. Conduct ethnographic interviews with survivors of prescription opioid overdoses, if 
feasible. 
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Recommendation on Naloxone Education and Distribution 
 
The Montgomery County Unintentional Prescription Drug Poisoning Coalition recommends 
deferring on a recommendation on the establishment of a naloxone education and 
distribution program in Montgomery County until additional study can be completed. The 
Coalition recognizes that naloxone education and distribution may be an effective method 
of preventing opioid overdose deaths among non-medical pain pill users; however, a 
number of issues regarding the establishment of such a program are unresolved, precluding 
a recommendation at this time. The following issues were of primary importance in the 
decision to continue to examine the issue: 
1. The suitability of naloxone education and distribution for the population of Montgomery 
County residents who are in danger of experiencing fatal overdoses is as of yet 
uncertain because: 
a. Poly-drug users with high rates of prescription opioid use, frequent exposure to 
sedatives (including frequent exposure to benzodiazepines along with opioids), 
and few instances of uncomplicated heroin overdose, may not benefit from 
naloxone programs as currently operated. 
Our Poison Death Reviews of selected 2008 and 2009 cases, the coalition’s 
examination of the 2010 deaths from January 1 - September 15, and a 
preliminary overview of hospital visits for overdoses, reveal drug use patterns 
that are significantly different from the heroin injection use which has been 
successfully addressed by naloxone distribution programs in several locales. 
b. There is a relatively low incidence of overdose that might have been prevented 
by family members or fellow users having access to naloxone. 
Of the 81 Montgomery County drug-related OD death cases reviewed so far in 
2010, approximately 85% were judged unlikely to have been prevented by the 
use of an opioid antagonist. In these instances, the Poison Death Review 
indicated that: (1) the decedent was alone at the time of the overdose; or (2) by-
standers or family members were not in the position to notice the symptoms of 
overdose during the period when opioid antagonists could have been effective.  
c. Based on our survey of first responders, it appears that the majority of 
professionals who directly respond to overdoses in Montgomery County, and 
who, therefore, are in a position to understand the possible impact of naloxone 
use by the public, have a very negative view of the propriety or potential 
effectiveness of naloxone distribution. 
First responders thought that overdose was a significant problem, but they were 
very pessimistic about the suitability or effectiveness of a naloxone distribution 
program. 
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2. Additional information and data may help clarify the appropriateness of naloxone 
distribution for Montgomery County. This will include: 
a. Examination of additional coroner cases to see if a higher percentage of cases 
where naloxone might help emerges; 
b. Reviewing peer-reviewed results of current naloxone programs in Boston and 
North Carolina, which may be available in the coming year;  
c. Further measures to bring clarity to the issue might include: 
i. Ethnographic interviews with OD survivors 
ii. Further on-line surveys (community- at- large, pharmacists, others) 
iii. Community symposium to discuss naloxone 
iv. First responder/prescriber/pharmacist education and focus groups. 
3. If further examination of the county’s unintentional poisoning data, results from 
interviews and surveys, and positive published results from other naloxone programs 
indicates that naloxone distribution might be an appropriate way to reduce 
unintentional OD fatalities, other significant issues to establishing a naloxone 
distribution program in Montgomery County need to be addressed. Some of these are: 
a. Garnering support from the health care community  
b. Garnering widespread community support. This might include: 
i. Surveying community attitudes and support for naloxone distribution 
ii. Education to increase community familiarity with purposes and 
mechanisms of a naloxone distribution program 
iii. Identifying or building an infrastructure to support a naloxone 
distribution program. Unlike Boston, which has a needle exchange 
programs, or Wilkes County, NC, where there is direct recruitment 
through a small number of prescribers, there is no ready-made 
infrastructure for  such a program in Montgomery County. 
c. Financial support is necessary. Funds are in short supply at this time. 
 
Potential Alternative Approach 
One alternative to traditional naloxone distribution programs that was discussed by the 
coalition and merits further consideration is predicated on naloxone education delivered by,  or 
through, prescribers and/or pharmacists, and a naloxone prescription that is paid for by a drug 
user (or his/her family). Thus, the cost (intra-nasal naloxone is approximately $30 for the 
customary 2 dose kit; injectable naloxone is typically supplied in two syringes, at a cost of 
around $2 per dose) would be borne by those use the service. Epinephrine injections for bee 
stings is an instructive model here.  
A recommendation on naloxone education and distribution will be made by the end of Year 2 of 
the project. 
